

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A10/2017 OS

DESPATCHED ON 03RD OCTOBER2017

HLA PHENOTYPE OF BLOOD DONOR: A2, -, B39, B61; Cw2, Cw-, DR4, DR13; DQ6, DQ7

				Summary of Results												
				PBL				T-Cells				B-Cells				
Total tested	Positive	Negative	NT/Equivocal	14	14	14	14	33	34	34	34	27	27	29	28	
% Positive	% Negative			0	0	0	0	0	0	0	1	27	2	0	1	
				12	14	14	14	33	34	34	33	0	25	29	27	
				1	1	1	1	5	4	4	4	12	12	10	11	
				14.3%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	2.9%	100.0%	7.4%	0.0%	3.6%	
				85.7%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	97.1%	0.0%	92.6%	100.0%	96.4%	
Consensus				Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
HLA Antibody Specificity (Defined By CDC)				DR5 DR6 DQ6	DQ3	B7 DR2	Multi	DR5 DR6 DQ6	DQ3	B7 DR2	Multi	DR5 DR6 DQ6	DQ3	B7 DR2	Multi	
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Without DTT				Without DTT				Without DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
101	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
112	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	Negative	Negative	Negative	The crossmatch with serum number one did not have the minimum cell number to validate the assay Crossmatches without DTT were not performed according to current protocol.
114																
116		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	
119	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
120		YES	YES													
128	YES	YES	YES	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
133	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Too low B-cells to be tested
139	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	
143	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Equivocal	Positive reactions with sera 3 and 4 in negative controls used
145	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
147	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	Agglutination of cells at reception with about 20% dead cells, and we harvested only 3.10exp6 cells that is insufficient in our routine work for CDC cross-matching. Unfortunately, there is no further material available to send to us as it is distributed equally between all participants on the distribution date.
154	YES	YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	
157	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
159	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
162	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
163	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
169	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
181	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
186	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
189	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
190	YES	YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability Crossmatch with B lymphocytes was NT : not enough B cells (clotted cells)
193	YES	YES	YES	NT	NT	NT	NT	Negative	Negative	Negative	Negative	NT	NT	NT	NT	
194	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
195	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
197	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
204	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
206	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
209	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	B-cells not routinely tested for deceased donors
216	YES	YES	YES	Negative	Negative	Negative	Negative									
223	YES	YES	YES					Negative	Negative	Negative	Negative	Equivocal	Equivocal	Equivocal	Equivocal	No results reported for B-cells due to low viability (equivocal) Not testing : technical failure
227	YES	YES	YES													
229	YES	YES	YES													
232	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
235	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
238	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
239	YES	YES	YES	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
245	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
252	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
260	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Equivocal	Negative	Negative	
268	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
284	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
292	YES	YES	YES					Negative	Negative	Negative	Positive	Positive	Negative	Negative	Negative	
293	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
294	YES	YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Negative	Positive	
297	YES	YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	After 2 sorting, there was no B-cells in the sample Insufficient number for T and B-cells Cell viability too low
321	YES	YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	
351	YES	YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A10/2017 OS

DESPATCHED ON 03RD OCTOBER2017

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101					1	1	1	1	8	1	1	1		100	100
112	1	1	1	1									90		
114					2	1	1	1	NT	1	1	1			
116					NT	NT	NT	NT	NT	NT	NT	NT		98	95
119	1	1	1	1									95		
120					1	1	1	1	8	1	1	1		80	80
128	4	1	1	1									90		
133					2	2	2	2	8	2	2	2	70	70	70
139	1	1	1	1	1	1	1	1	NT	NT	NT	NT	80	80	0
143					1	1	1	1						82	
145					-	-	-	-	8	4-8	-	Equivocal		100	100
147	1	1	1	1	1	1	1	1	8	1	1	1	100	100	80
154					NT	NT	NT	NT	NT	NT	NT	NT			
157					1	1	1	1	8	1	1	1		100	80
159					1	1	1	1	6	1	1	1		99	99
162					1	1	1	1	8	1	1	1		100	100
163					1	1	1	1	8	1	1	1		90	90
169					1	1	1	1	8	1	1	1		98	97
181					1	1	1	1	8	1	2	2		100	100
186					0	0	0	0	6	0	0	0		99	99
189	1	1	1	1									93		
190					5	5	5	5	NT	NT	NT	NT		95	
193	NT	NT	NT	NT	1	1	1	1	NT	NT	NT	NT		99	
194					1	1	1	1	8	1	1	1	95	98	90
195					2	2	2	2	8	2	2	2		80	65
197					-	-	-	-	-	-	-	-	70	70	70
204					2	1	1	1	8	2	1	2		90	90
206					-	-	-	-	8	-	-	-		100	70
209	1	1	1	1					NT	NT	NT	NT	95		
216	1	1	2	2									95		
223					2	1	1	1	Equivocal	Equivocal	Equivocal	Equivocal		95	50
227					NT	1	1	1	NT	NT	1	1		90	90
229															
232	0	0	0	0									80		
235	1	1	1	1									85		
238	2	1	1	1	1	1	1	1	6	2	2	1	95	95	80
239	4	-	-	-	-	-	-	-	8	-	-	-	99	99	99
245	1	1	1	1	1	1	1	1	8	1	1	1	100	100	100
252	1	1	1	1					6	1	1	1	65		55
260					-	-	-	-	++++	Equivocal	-	-		90	90
268					1	1	1	1	6	1	1	1		85	95
284					1	1	1	1	8	1	1	1		99	90
292					1	1	1	4	8	1	1	1		90	30
293					0	0	0	0	6+	0	0	0		90	80
294					0	0	0	0	8	6	2	6		95	95
297					1	1	1	1	NT	NT	NT	NT	80	80	0
321					NT	NT	NT	NT	NT	NT	NT	NT			
351					NT	NT	NT	NT	NT	NT	NT	NT			

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A10/2017 OS

DESPATCHED ON 03RD OCTOBER2017

HLA PHENOTYPE OF BLOOD DONOR: A2, -; B39, B61; Cw2, Cw-; DR4, DR13; DQ6, DQ7

	Summary of Results											
	PBL				T-Cells				B-Cells			
Total tested	12	12	12	12	31	32	32	32	26	26	28	27
Positive	0	0	0	0	0	0	0	0	26	1	0	0
Negative	12	12	12	12	31	32	32	32	0	25	28	27
NT/Equivocal	1	1	1	1	3	2	2	2	10	10	8	9
% Positive	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%	3.8%	0.0%	0.0%
% Negative	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	96.2%	100.0%	100.0%
<b>Consensus</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Positive</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>
HLA Antibody Specificity (Defined By CDC)	DR5 DR6 DQ6	DQ3	B7 DR2	Multi	DR5 DR6 DQ6	DQ3	B7 DR2	Multi	DR5 DR6 DQ6	DQ3	B7 DR2	Multi

Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments		
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4			
101		YES	YES															
112	YES		YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	The crossmatch with serum number one did not have the minimum cell number to validate the assay
114		YES	YES											NT	Negative	Negative	Negative	
116		YES	YES											Positive	Negative	Negative	Negative	Crossmatches without DTT were not performed according to current protocol.
119	YES		YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative					
120		YES	YES											Positive	Negative	Negative	Negative	
133		YES	YES											Positive	Negative	Negative	Negative	
139	YES	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	
143		YES	YES															
147	YES	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
157		YES	YES											NT	NT	NT	NT	Low cell count, not enough sample to perform test with DTT
159		YES	YES											Positive	Negative	Negative	Negative	
162		YES	YES											Positive	Negative	Negative	Negative	
163		YES	YES											Positive	Negative	Negative	Negative	
169		YES	YES											Positive	Negative	Negative	Negative	
181		YES	YES											Positive	Negative	Negative	Negative	
186		YES	YES											Positive	Negative	Negative	Negative	
189	YES		YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
190		YES	YES											NT	NT	NT	NT	Low B-cell viability
193	YES	YES	YES		NT	NT	NT	NT	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	
194		YES	YES											Positive	Negative	Negative	Negative	
195		YES	YES											Positive	Negative	Negative	Negative	
197		YES	YES											Positive	Negative	Negative	Negative	
204		YES	YES											Positive	Negative	Negative	Negative	
206		YES	YES											Positive	Negative	Negative	Negative	
209	YES		YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	B-cells not routinely tested for deceased donors
216	YES		YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative					
227		YES	YES											NT	NT	Negative	Negative	Not testing : technical failure
229	YES																	
235	YES				Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
238	YES	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
245	YES	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
252	YES		YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
260		YES	YES											Positive	Equivocal	Negative	Negative	
262		YES	YES											Positive	Positive	Negative	Equivocal	
268	YES	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
284		YES	YES											Positive	Negative	Negative	Negative	
292		YES	YES											Positive	Negative	Negative	Negative	
293		YES	YES											Positive	Negative	Negative	Negative	
294		YES	YES											Positive	Negative	Negative	Negative	
297		YES	YES											Positive	Negative	Negative	Negative	
321		YES	YES											NT	NT	NT	NT	After 2 sorting, there was no B-cells in the sample
351		YES	YES		NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A10/2017 OS

DESPATCHED ON 03RD OCTOBER2017

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101					1	1	1	1	8	1	1	1	90	100	100
112	1	1	1	1											
114					1	1	1	1	NT	1	1	1			
116					1	1	1	1	2-8	1	1	1-2		98	95
119	1	1	1	1									95		
120					1	1	1	1	8	1	1	1		80	80
133					2	2	2	2	8	2	2	2	70	70	70
139	1	1	1	1	1	1	1	1	NT	NT	NT	NT	80	80	0
143					2	2	2	1						82	
147	1	1	1	1	1	1	1	1	8	1	1	1	100	100	80
157									NT	NT	NT	NT		100	80
159					1	1	1	1	6	1	1	1		99	99
162					1	1	1	1	8	1	1	1		100	100
163					1	1	1	1	8	1	1	1		90	90
169					1	1	1	1	8	1	1	1		98	97
181					1	1	1	1	8	1	2	1		100	100
186					0	0	0	0	6	0	0	0		99	99
189	1	1	1	1									93		
190					5	5	5	5	NT	NT	NT	NT		95	
193	NT	NT	NT	NT	1	1	1	1	NT	NT	NT	NT		99	
194					1	1	1	1	8	1	1	1	95	98	90
195					2	2	2	2	8	2	2	2		80	65
197					-	-	-	-	-	-	-	-	70	70	70
204					2	1	1	1	8	1	1	1		90	90
206					-	-	-	-	6	-	-	-		100	70
209	1	1	1	1					NT	NT	NT	NT	95		
216	1	1	2	2									95		
227					NT	1	1	1	NT	NT	1	1		90	90
229															
235	-	-	-	-									85		
238	2	1	1	1	1	1	1	1	6	1	1	1	95	95	80
245	1	1	1	1	1	1	1	1	8	1	1	1	100	100	100
252	1	1	1	1					6	1	1	1	65		55
260					-	-	-	-	++++	Equivocal	-	-		90	90
262	1	1	1	1	1	1	1	1	8	6	1	4	100	100	100
268					1	1	1	1	6	1	1	1		85	95
284					1	1	1	1	8	1	1	1		99	90
292					1	1	1	1	8	1	1	1		90	30
293					0	0	0	0	6+	0	0	0		90	80
294					0	0	0	0	8	0	0	0		95	95
297					1	1	1	1	NT	NT	NT	NT	80	80	0
321					NT	NT	NT	NT	NT	NT	NT	NT			
351					NT	NT	NT	NT	NT	NT	NT	NT			